Andrew Oxtoby
CIK 1765473 · See Remarks · last filed 2026-03-20
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
4
Total Filings
13
Lifetime Open-Market Net
$44.3K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KLRS | See Remarks | — | $4.33 | — | $0 | 2 | 2026-03-20 |
| Kalaris Therapeutics, Inc. (ALVR) Delisted | See Remarks | — | $9.81 | — | $0 | 1 | 2025-03-18 |
| CHINOOK THERAPEUTICS, INC. (KDNY) Delisted | Chief Commercial Officer | — | $40.39 | — | $0 | 2 | 2023-08-11 |
| COLL | Chief Commercial Officer | 0 | $34.64 | $0 | $44.3K | 8 | 2020-10-14 |
Recent Filings · Page 2 of 2
13 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-03-04 | COLL | Grant (A) | +11,250 | $0 | EDGAR |
| 2020-03-03 | COLL | Grant (A) | +11,250 | $0 | EDGAR |
| 2019-01-24 | COLL | Grant (A) | +12,000 | $0 | EDGAR |
Showing 11–13 of 13
Prev
Page 2 of 2
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.